研究人员开发了一种高特异性的CDC7抑制剂TAK-931作为临床肿瘤治疗剂，抗肿瘤药效研究通过美迪西进行

Cell division cycle 7 (CDC7) plays important roles in DNA replication. Researchers developed a highly specific CDC7 inhibitor, TAK-931, as a clinical cancer therapeutic agent. The antitumor efficacy studies in PDX models were performed at Medicilon. 

Medicilon has established a complete evaluation system for preclinical anti-tumor efficacy, and has more than 200 different types of tumor efficacy models.

Reference:

Kenichi Iwai, A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recovery. Sci Adv. 2021 May 21;7(21):eabf0197. doi: 10.1126/sciadv.abf0197.